July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee (PCAC)
FDA / PCAC — official records & coverage — July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee (PCAC)
Channel: U.S. Food and Drug Administration · Our label: Government proceedings and coverage of them · OFFICIAL — government record · Source: youtube.com/watch?v=DhDC0DAYdBI
What this video covers
I would first like to remind everyone to please mute your line when you are not speaking. All members of the public are reminded to silence their phones and other devices and to otherwise refrain from disrupting the meeting. Loud talking or applause may make it difficult for meeting participants and observers to hear the proceedings. My name is Brian Saraga and I will be chairing today’s meeting.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- BPC 157 related BDS’s which are BPC 157 freebase, BPC 157 acetate, KPV related BDS’s which are KPV freebase and KPV acetate.
- Thus, allowing these products to be compounded would ex would uh expose consumers to unproven products and displace existing safe, effective, and proven FDA uh approved products, creating a real risk of clinical harm.
- Any company that aspires to prove the safety and effectiveness of a peptide will turn away from them knowing that compounders will simply be able to sell them without ever needing to generate safety and effectiveness evidence.
- Listing BPC 157 would confuse patients and mislead them into thinking the FDA has fully endorsed PPC 157 despite major evidence gaps, especially compared to other 503A boxless substances and FDA approved options.
- Additionally, listing BPC 157 would undermine the integrity of the FDA drug approval framework as presented by the previous individual and would create a wide bypass for FDA clinical trials and approved requirements.
- At the time of this evaluation, the nominators did not submit and FDA did not identify clinical studies in humans assessing pharmacocinetics, non-clinical pharmacocinetics or toxicinetic studies of KPV.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.